A Study of Lapatinib in Combination With Caelyx in Patients With Advanced HER2 Positive Pretreated Breast Cancer

NCT02131506 · clinicaltrials.gov ↗

PHASE1

Phase

TERMINATED

Status

11

Enrollment

OTHER

Sponsor class

Stopped Safety reasons

Conditions

HER-2 Positive Breast Cancer
Malignant Neoplasm of Breast

Interventions

DRUG: Lapatinib, Caelyx

Sponsor

Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS